Lighthouse Pharmaceuticals is a clinical-stage biopharmaceutical company whose lead clinical program is LHP588, an oral once-daily small-molecule therapy. LHP588 is being evaluated in the SPRING Phase 2 double-blind placebo-controlled trial in patients with P. gingivalis–positive mild to moderate Alzheimer's disease, and the trial is enrolling across the United States. The SPRING study is supported by a $49.2 million grant from the National Institute on Aging. Lighthouse plans to use proceeds from its Series A financing to advance LHP588 through the SPRING trial and to expand its pipeline. The company describes its approach as targeting a defined subset of Alzheimer's disease and aims to move LHP588 toward late-stage development.

Total raised

$12M

Funding rounds

1

Latest round

Series A

Latest activity

Apr 2026